Study record · Thymosin alpha-1

TESTS Phase III thymosin alpha-1 sepsis trial

Mortality was 23.4% versus 24.1% (HR≈0.99; P=.93): no mortality benefit.

Key result

Mortality was 23.4% versus 24.1% (HR≈0.99; P=.93): no mortality benefit.

Study designRandomized multicenter controlled trial

PhasePhase III

PopulationAdults with sepsis

Sample size1106

RouteSubcutaneous

Regimen / exposureEvery 12 hours for 7 days; abstract does not provide per-dose amount

Duration7 days

ComparatorControl

Primary endpoint / question28-day all-cause mortality

Safety resultNo major significant difference in secondary/safety outcomes reported in abstract.

Key limitationsLarge negative trial should temper conclusions from smaller/older heterogeneous studies and meta-analyses.

Registry / identifierPMID 39814420